Skip to main content

Table 3 Dot blot analysis of tyrosine receptor kinase phosphorylation in SW1736, HTh7, BHT101 and ML1 cells after short-term (10 min) treatment with 3 μM sorafenib

From: Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

  % of untreated control
Protein SW1736 HTh7 BHT101 ML1
p-VEGFR1 41.3 ± 7.2* 27.2 ± 11.5* 62.5 ± 7.4* 70.3 ± 4.6*
p-VEGFR2 30.3 ± 10.2* 45.7 ± 8.8* 60.7 ± 5.7* 75.6 ± 6.7*
p-VEGFR3 44.2 ± 7.2* 67.9 ± 8.9* 68.3 ± 10.4* 94.1 ± 7.1
p-PDGFRA 46.6 ± 6.0* 28.5 ± 11.1* n.e. n.e.
p-PDGFRB 67.0 ± 8.1* 57.3 ± 6.8* 67.2 ± 10.9* 64.2 ± 9.0*
p-EGFR 102.8 ± 7.8 107.4 ± 10.4 105.0 ± 7.3 93.0 ± 11.4
p-ERBB2 96.3 ± 6.9 91.8 ± 9.9 101.5 ± 11.8 101.9 ± 9.3
p-ERBB3 111.3 ± 8.8 108.7 ± 7.4 95.3 ± 10.8 96.2 ± 11.6
p-ERBB4 107.5 ± 11.0 110.3 ± 12.4 94.9 ± 10.71 102.6 ± 7.8
p-insulinR 103.9 ± 6.9 97.7 ± 10.3 96.6 ± 8.8 112.1 ± 12.0
p-IGF1R 112.6 ± 10.5 101.8 ± 9.9 95.9 ± 8.9 110.3 ± 10.3
  1. VEGFR: vascular endothelial growth factor receptor, PDGFR: platelet-derived growth factor receptor, EGFR: epidermal growth factor receptor, IGF1R: insulin-like growth factor 1 receptor, n.e.: not expressed.
  2. Values for the respective protein compared to the vehicle-treated control ± standard deviation are depicted and represent 6-fold determinations. *indicates significant decrease (p<0.05, Student’s t-test).